Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Sonal Singh, Yoon K. Loke, John G. Spangler and Curt D. Furberg
CMAJ September 06, 2011 183 (12) 1359-1366; DOI: https://doi.org/10.1503/cmaj.110218
Sonal Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ssingh31@jhu.edu
Yoon K. Loke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John G. Spangler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Curt D. Furberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    Selection of double-blind placebo-controlled randomized controlled trials (RCTs) for inclusion in the systematic review and meta-analysis of the risk of serious adverse cardiovascular events associated with varenicline use. *An additional open-label trial of varenicline versus nicotine replacement therapy was included in the sensitivity analysis.

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    Meta-analysis of double-blind placebo-controlled randomized trials of the risk of serious adverse cardiovascular events associated with the use of varenicline. An odds ratio (OR) greater than 1.0 indicates an increased risk of a serious adverse cardiovascular event. CI = confidence interval.

Tables

  • Figures
    • View popup
    • Download powerpoint
    Table 1:

    Characteristics of randomized controlled trials of varenicline included in the analysis of serious adverse cardiovascular events*

    Table 1:
    • View popup
    • Download powerpoint
    Table 2:

    Risk-of-bias assessment of randomized controlled trials (RCTs) of varenicline included in the analysis of serious adverse cardiovascular events*

    Table 2:
    • View popup
    • Download powerpoint
    Table 3:

    Sensitivity analyses for the outcome of serious adverse cardiovascular events*

    Table 3:
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (12)
CMAJ
Vol. 183, Issue 12
6 Sep 2011
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
Sonal Singh, Yoon K. Loke, John G. Spangler, Curt D. Furberg
CMAJ Sep 2011, 183 (12) 1359-1366; DOI: 10.1503/cmaj.110218

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
Sonal Singh, Yoon K. Loke, John G. Spangler, Curt D. Furberg
CMAJ Sep 2011, 183 (12) 1359-1366; DOI: 10.1503/cmaj.110218
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Varenicline for smoking cessation: Is it a heartbreaker?
  • Varenicline: quantifying the risk
  • Varenicline: quantifying the risk
  • Varenicline: quantifying the risk
  • Varenicline: quantifying the risk
  • PubMed
  • Google Scholar

Cited By...

  • 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
  • Reprint of: Prevention and Treatment of Tobacco Use: JACC Health Promotion Series
  • Prevention and Treatment of Tobacco Use: JACC Health Promotion Series
  • Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital
  • Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review
  • Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease
  • Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials
  • Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
  • Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  • Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome
  • What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study
  • Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis
  • Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database
  • Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
  • The Effects of Nutritional Deficiencies, Smoking, and Systemic Disease on Orthopaedic Outcomes
  • Does smoking cessation with varenicline worsen vascular endothelial function?
  • Choice of summary statistics: relative and absolute measures
  • Bupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction: A Randomized, Placebo-Controlled Trial
  • Smoking Cessation After Acute Myocardial Infarction
  • Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study
  • Reducing the Cardiovascular Disease Burden: Justified Means for Getting to the End
  • AAV-Directed Persistent Expression of a Gene Encoding Anti-Nicotine Antibody for Smoking Cessation
  • Flaws in analysis lead to misleading conclusions about varenicline's safety in smoking cessation
  • Authors' reply to Singh and Loke
  • Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence
  • Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
  • Authors' response
  • Varenicline: quantifying the risk
  • Varenicline: quantifying the risk
  • Varenicline: quantifying the risk
  • Varenicline: cardiovascular safety
  • Varenicline for smoking cessation: Is it a heartbreaker?
  • Varenicline: quantifying the risk
  • Varenicline: quantifying the risk
  • Authors' response
  • Google Scholar

More in this TOC Section

  • Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation
  • Emergency department use following incentives to provide after-hours primary care: a retrospective cohort study
  • Physician choices in pulmonary embolism testing
Show more Research

Similar Articles

Collections

  • Topics
    • Tobacco control & smoking
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire